Nucleic acid testing (NAT) or nucleic acid amplification test (NAAT) is one of the advanced diagnostic test increasingly gaining traction over conventional culture methods, owing to high efficiency and accuracy. Furthermore, nucleic acid testing has potential application in various life threating diseases including cancer, infectious disease, genetic and mitochondrial disorders, and also in development of personalized and precision medicine. NAT is an efficient diagnostic method, which significantly reduces the procedural time and consumption of reagents. Moreover, nucleic acid testing is increasingly being used for screening blood donation samples to reduce the risk of transfusion transmitted infections (TTIs), thus aiding in growth of the nucleic acid testing market.
Nucleic Acid Testing Market – Driver
Nucleic acid tests are extensively used for screening and diagnosis of various infectious diseases. Moreover, growing prevalence of infectious diseases and management of epidemics of new diseases has led to increasing demand for advanced diagnostic tests such as nucleic acid testing. For instance, according to the World Health Organization (WHO), in 2015, around 32,000 estimated deaths from tuberculosis and around 3, 23,000 new cases of TB were registered in the European region. Furthermore, according to the Centers for Disease Control and Prevention (CDC), around 5,251 deaths due to influenza infection were registered in 2015, in the U.S.
Nucleic Acid Testing Market – Competitive Analysis
Key market players in nucleic acid testing market are Abbott Laboratories, Beckman Coulter, Inc., Becton, Dickinson and Company, BioMérieux SA, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Grifols, S.A., Illumina, Inc., Novartis Ag, Qiagen N.V., Quest Diagnostics Incorporated, Siemens Ag, and Tecan Group Ltd., among others. Players in the market are focusing on inorganic growth strategies, in order to enhance its market share and remain competitive in the market. For instance, in January 2017, Grifols, S.A. acquired the NAT (Nucleic Acid Testing) donor screening unit from Hologic, Inc. for US$ 1,850 million. The acquisition enabled Grifols to strengthen its position in transfusion medicine through NAT technology.